• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Esperion Therapeutics, Inc. - Common Stock (NQ:ESPR)

    3.160 -0.010 (-0.31%)
    Streaming Delayed Price Updated: 2:18 PM EDT, Jun 29, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 4,534,692
    Open 3.170
    Bid (Size) 3.160 (75,000)
    Ask (Size) 3.170 (502,300)
    Prev. Close 3.170
    Today's Range 3.160 - 3.170
    52wk Range 0.9490 - 4.175
    Shares Outstanding 28,277,493
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. - ESPR
    From Kahn Swick & Foti, LLC
    Via Business Wire
    News headline image
    Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -14.8%
    -14.8%
    1 Month
    +1.0%
    +1.0%
    3 Month
    +20.2%
    +20.2%
    6 Month
    -18.8%
    -18.8%
    1 Year
    +221.0%
    +221.0%

    More News

    Read More
    News headline image
    Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    Friday's session: most active stocks ↗
    Via Chartmill
    Esperion Therapeutics Inc (NASDAQ:ESPR) Reports Mixed Q4 2025 Results Amid Strategic Expansion ↗
    Via Chartmill
    News headline image
    Halper Sadeh LLC is Investigating Whether SILA, ESPR, CRBG, EQH are Obtaining Fair Deals for their Shareholders
    From Halper Sadeh LLC
    Via GlobeNewswire
    News headline image
    Halper Sadeh LLC is Investigating Whether SILA, LSTA, ESPR are Obtaining Fair Deals for their Shareholders
    From Halper Sadeh LLC
    Via GlobeNewswire
    News headline image
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Esperion Therapeutics, Inc. (Nasdaq – ESPR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq – LSTA), SkyWater Technology, Inc. (Nasdaq -
    From Brodsky & Smith LLC
    Via GlobeNewswire
    News headline image
    Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. - ESPR
    From Kahn Swick & Foti, LLC
    Via Business Wire
    What's going on in today's session ↗
    Via Chartmill
    News headline image
    Veeva Systems, Five9, AXT And Other Big Stocks Moving Higher On Friday ↗
    Via Benzinga
    Topics Artificial Intelligence Stocks
    Which stocks are moving on Friday? ↗
    Via Chartmill
    Let's uncover which stocks are experiencing notable gaps during today's session. ↗
    Via Chartmill
    News headline image
    ESPR Stock Alert: Halper Sadeh LLC is Investigating Whether Esperion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders
    From Halper Sadeh LLC
    Via Business Wire
    Stay updated with the stocks that are on the move in today's pre-market session. ↗
    Via Chartmill
    News headline image
    Esperion to be Acquired by ARCHIMED
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Esperion to Report First Quarter 2026 Financial Results on May 7
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics
    From Athyrium Capital Management, LP
    Via GlobeNewswire
    News headline image
    Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Esperion to Participate in 25th Annual Needham Virtual Healthcare Conference
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) at the American College of Cardiology’s Annual Scientific Session 2026
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    ESPR Stock Falls After Esperion’s Mixed Q4 — Retail Remains Unfazed, Eyes ‘Massive’ Upcoming Catalysts ↗
    Via Stocktwits
    Topics Intellectual Property

    Frequently Asked Questions

    Is Esperion Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Esperion Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Esperion Therapeutics, Inc. - Common Stock trade on?
    Esperion Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Esperion Therapeutics, Inc. - Common Stock?
    The ticker symbol for Esperion Therapeutics, Inc. - Common Stock is ESPR on the Nasdaq Stock Market
    What is the current price of Esperion Therapeutics, Inc. - Common Stock?
    The current price of Esperion Therapeutics, Inc. - Common Stock is 3.160
    When was Esperion Therapeutics, Inc. - Common Stock last traded?
    The last trade of Esperion Therapeutics, Inc. - Common Stock was at 06/29/26 02:18 PM ET
    What is the market capitalization of Esperion Therapeutics, Inc. - Common Stock?
    The market capitalization of Esperion Therapeutics, Inc. - Common Stock is 89.36M
    How many shares of Esperion Therapeutics, Inc. - Common Stock are outstanding?
    Esperion Therapeutics, Inc. - Common Stock has 89M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.